• AHA Late-Breaker ARTESiA: Apixaban for the Prevention of Stroke in Patients With Subclinical AF

  • Feb 20 2024
  • Length: 14 mins
  • Podcast

AHA Late-Breaker ARTESiA: Apixaban for the Prevention of Stroke in Patients With Subclinical AF By cover art

AHA Late-Breaker ARTESiA: Apixaban for the Prevention of Stroke in Patients With Subclinical AF

Listen for free

View show details

  • Summary

  • Continuous cardiac monitoring detects brief, asymptomatic, heart rhythm abnormalities in one-third of older individuals and these symptoms are associated with an increased risk of stroke.

    The ARTESiA trial clearly demonstrates that use of the blood thinner apixaban reduces patient risk of stroke compared to treatment with aspirin, but is associated with an increased risk of bleeding.

    In this interview, Jeff S. Healey, MD, and Thomas F. Deering MD, FACC, discuss AHA Late-Breaker: Apixaban for the Prevention of Stroke in Patients With Subclinical Atrial Fibrillation.

    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

    Show more Show less
activate_primeday_promo_in_buybox_DT
Physical Illness & Disease Hygiene & Healthy Living
Show more Show less

What listeners say about AHA Late-Breaker ARTESiA: Apixaban for the Prevention of Stroke in Patients With Subclinical AF

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available